Tailoring Bruton Tyrosine Kinase Inhibitor Strategies for CLL: Managing Today, Anticipating Tomorrow Keeping Current

Are you selecting the right Bruton tyrosine kinase (BTK) inhibitor for your patients with chronic lymphocytic leukemia (CLL)? Experts discuss the key differentiators and upcoming developments in the field.
  
Credit available for this activity expires: 04/26/25
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000717?ecd=bdc_podcast_libsyn_mscpedu